High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/ hepatitis B e antigen-positive patients after living donor liver transplantation

World Journal of Gastroenterology

Volumn 22, Issue 14, 2016, Pages 3803-3812

  Lee, Eung Chang ^a   Kim, Seong Hoon ^a   Lee, Seung Duk ^a   Park, Hyeongmin ^a   Lee, Soon Ae ^a   Park, Sang Jae ^a  

^a National Cancer Center   (South Korea)

Author keywords

Hepatitis B e antigen; Hepatitis B immune globulin; Hepatitis B virus DNA; Hepatocellular carcinoma; Liver transplantation

Indexed keywords

ALPHA FETOPROTEIN; BASILIXIMAB; CORTICOSTEROID; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; MYCOPHENOLATE MOFETIL; TACROLIMUS; BIOLOGICAL MARKER; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; VIRUS DNA;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD PUGH SCORE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LIVING DONOR LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROPENSITY SCORE; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; COMPLICATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; HEPATITIS B; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MORTALITY; PROCEDURES; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROPENSITY SCORE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84962655663     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i14.3803     Document Type: Article

References (42)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]
2. Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol 2009; 15 Suppl 6: S50-S59 [PMID: 20037280 DOI: 10.3350/kjhep.2009.15.S6.S50]
3. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540 [PMID: 15048797 DOI: 10.1002/lt.20128]
4. Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, Montalto F, Coppa J, Mazzaferro V. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998; 5: 29-34 [PMID: 9683751 DOI: 10.1007/PL00009947]
5. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation-an emerging clinical challenge. Transpl Int 2013; 26: 109-118 [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x]
6. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, Bismuth H. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-815 [PMID: 1672913 DOI: 10.1016/0140-6736(91)9251 5-4]
7. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-1586 [PMID: 10216146 DOI: 10.1002/hep.510290507]
8. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133 [PMID: 6118576 DOI: 10.1016/S0140-6736(81)90585-7]
9. Kew MC. Hepatitis viruses and hepatocellular carcinoma. Res Virol 1998; 149: 257-262 [PMID: 9879602 DOI: 10.1016/S0923-2516(99)89003-7]
10. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103: 1663-1673 [PMID: 18616655 DOI: 10.1111/j.1572-0241.2008.01872.x]
11. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-897 [PMID: 19747749 DOI: 10.1016/j.jhep.2009.07.009]
12. Ho SK, Chan TM, Cheng IK, Lai KN. Comparison of the secondgeneration digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum. J Clin Microbiol 1999; 37: 2461-2465 [PMID: 10405385]
13. Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, Franchello A, Colucci G, Ghisetti V. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: A novel automated realtime PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol 2007; 45: 828-834 [PMID: 17229858 DOI: 10.1128/JCM.00914-06]
14. Daniel HD, Fletcher JG, Chandy GM, Abraham P. Quantitation of hepatitis B virus DNA in plasma using a sensitive cost-effective "in-house" real-time PCR assay. Indian J Med Microbiol 2009; 27: 111-115 [PMID: 19384032 DOI: 10.4103/0255-0857.45362]
15. Ciotti M, Marcuccilli F, Guenci T, Prignano MG, Perno CF. Evaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B. J Clin Microbiol 2008; 46: 1517-1519 [PMID: 18272717 DOI: 10.1128/JCM.02046-07]
16. Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A, Thamm S, Zoulim F. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol 2007; 45: 3948-3953 [PMID: 17942654 DOI: 10.1128/JCM.01180-07]
17. Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, Nashan B, Kubicka S, Maschek H, Tusch G, Raab R, Ringe B, Manns MP, Pichlmayr R. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999; 17: 324-331 [PMID: 10458250]
18. Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, Neuhaus R, Berg T, Hopf U, Neuhaus P. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535 [PMID: 12029640 DOI: 10.1053/jhep.2002.33681]
19. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003; 98: 151-159 [PMID: 12526951 DOI: 10.1111/j.1572-0241.2003.07178.x]
20. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, Lee SK, Kim SI, Lee KU. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13: 451-458 [PMID: 17318862 DOI: 10.1002/lt.21043]
21. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-189; quiz 2155 [PMID: 18424269 DOI: 10.1053/j.gastro.2008.02.064]
22. Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K, Hirohata S, Tatsukawa M, Kawai D, Shiraha H, Miyake Y, Ikeda F, Kobashi H, Matsuda H, Shinoura S, Yoshida R, Satoh D, Utsumi M, Onishi T, Yamamoto K. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int 2011; 5: 918-926 [PMID: 21484119 DOI: 10.1007/s12072-011-9265-z]
23. Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat 2013; 2013: 259148 [PMID: 23533738 DOI: 10.1155/2013/259148]
24. Hollinger FB, Sood G. Occult hepatitis B virus infection: A covert operation. J Viral Hepat 2010; 17: 1-15 [PMID: 20002296 DOI: 10.1111/j.1365-2893.2009.01245.x]
25. Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, Marchiaro G, Salizzoni M, Rizzetto M. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl 2004; 10: 356-362 [PMID: 15004761 DOI: 10.1002/lt.20093]
26. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174 [PMID: 12124405 DOI: 10.1056/NEJMoa013215]
27. Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Bréchot C, Paterlini-Bréchot P. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005; 54: 1162-1168 [PMID: 16009689 DOI: 10.1136/gut.2004.054452]
28. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. Hepatology 2000; 32: 1189-1195 [PMID: 11093723 DOI: 10.1053/jhep.2000.19789]
29. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, Ryan TS, Kuhns M, McNamara A, Caldwell SH, Abdulkareem A, Pruett TL. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-850 [PMID: 9637547 DOI: 10.1097/00000658-199806000-00007]
30. Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77: 8882-8892 [PMID: 12885906 DOI: 10.1128/JVI.77.16.8882-8892.2003]
31. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847 [PMID: 8247035 DOI: 10.1056/NEJM199312163292503]
32. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, Sun TS, Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebocontrolled trial. Hepatology 1983; 3: 135-141 [PMID: 6339349 DOI: 10.1002/hep.1840030201]
33. Committee for Proprietary Medicinal Products. Core SPC for human plasma derived hepatitis-B immunoglobulin for intravenous use (CPMP/BPWG/4027/02). London, UK: The European Agency for the Evaluation of Medicinal Products, 2003
34. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695 [PMID: 17110329 DOI: 10.1016/j.cell.2006.11.001]
35. Takaki A, Yagi T, Yamamoto K. Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res 2015; 45: 38-47 [PMID: 24905970 DOI: 10.1111/hepr.12368]
36. Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003; 75: S41-S44 [PMID: 12589139]
37. Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002; 8: S67-S73 [PMID: 12362302]
38. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine-and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001; 8: 237-247 [PMID: 11385295 DOI: 10.1007/BF02256597]
39. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61: 766-768 [PMID: 18218641 DOI: 10.1093/jac/dkn014]
40. Ijaz S, Torre F, Tedder RS, Williams R, Naoumov NV. Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. J Med Virol 2001; 63: 210-216 [PMID: 11170059 DOI: 10.1002/1096-90 71(200103)63]
41. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Büschenfelde KH, Neuhaus P, Gerken G. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-263 [PMID: 9425945 DOI: 10.1002/hep.510270138]
42. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI, Tong MJ, Busuttil RW. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-1534 [PMID: 19877207 DOI: 10.1002/lt.21882]